Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study

被引：21
|
作者：
Wessels, Alette M. [1 ]
Bies, Robert R. [1 ,2 ]
Pollock, Bruce G. [2 ,3 ,4 ]
Schneider, Lon S. [5 ]
Lieberman, Jeffrey A. [6 ,9 ,10 ,11 ,12 ,13 ,14 ]
Stroup, Scott [6 ]
Li, Claire H. [1 ]
Coley, Kim [7 ]
Kirshner, Margaret M. [4 ]
Marder, Stephen R. [8 ,15 ,16 ,17 ,18 ,19 ,20 ]
机构：
[1] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN USA
[2] Univ Toronto, Ctr Addict & Mental Hlth, Toronto, ON, Canada
[3] Univ Toronto, Baycrest Hosp, Rotman Res Inst, Toronto, ON, Canada
[4] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[5] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[6] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA
[7] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA
[8] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA
[9] GlaxoSmithKline, London, England
[10] Intracellular Therapies, New York, NY 10032 USA
[11] Eli Lilly & Co, Indianapolis, IN USA
[12] Pierre Fabre, Castres, France
[13] Psychogenics, Tarrytown, NY USA
[14] Wyeth, Madison, NJ USA
[15] Advisory Board Wyeth, Madison, NJ USA
[16] Otsuka, Tokyo, Japan
[17] Sanofi Aventis, Bombay, Maharashtra, India
[18] Lundbeck, Copenhagen, Denmark
[19] Pfizer, New York, NY USA
[20] Schering Plough Corp, Kenilworth, NJ 07033 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 11期
基金：
加拿大健康研究院;
关键词：
ziprasidone; population pharmacokinetics; schizophrenia; CLINICAL ANTIPSYCHOTIC TRIALS; PROJECT; IMPACT; DRUG; RACE;
D O I：
10.1177/0091270010387604
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：1587 / 1591
页数：5
相关论文
共 50 条
  • [21] Physiologically-based pharmacokinetic modeling of ziprasidone in pregnant women
    Biesdorf, Carla
    Martins, Frederico
    Diniz, Andrea
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S12 - S13
  • [22] Clinical determinants of life satisfaction in chronic schizophrenia: Data from the CATIE study
    Fervaha, Gagan
    Agid, Ofer
    Takeuchi, Hiroyoshi
    Foussias, George
    Remington, Gary
    SCHIZOPHRENIA RESEARCH, 2013, 151 (1-3) : 203 - 208
  • [23] Drug and alcohol trajectories among adults with schizophrenia: Data from the CATIE study
    Van Dorn, Richard A.
    Desmarais, Sarah L.
    Tueller, Stephen J.
    Jolley, Jennifer M.
    Johnson, Kiersten L.
    Swartz, Marvin S.
    SCHIZOPHRENIA RESEARCH, 2013, 148 (1-3) : 126 - 129
  • [24] Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling
    Pinder, Nadine
    Zimmermann, Johannes B.
    Gastine, Silke
    Wuerthwein, Gudrun
    Hempel, Georg
    Bruckner, Thomas
    Hoppe-Tichy, Torsten
    Weigand, Markus A.
    Swoboda, Stefanie
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 118
  • [25] A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
    Goff, DC
    Sullivan, LM
    McEvoy, JP
    Meyer, JM
    Nasrallah, HA
    Daumit, GL
    Lamberti, S
    D'Agostino, RB
    Stroup, TS
    Davis, S
    Lieberman, JA
    SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : 45 - 53
  • [26] Effects of ziprasidone on cognitive function in patients with schizophrenia
    Harvey, PD
    Simpson, GM
    Siu, CO
    Romano, SJ
    Loebel, A
    BIOLOGICAL PSYCHIATRY, 2003, 53 (08) : 124S - 124S
  • [27] Population Pharmacokinetic Modeling of Pantoprazole in Pediatric Patients From Birth to 16 Years
    Knebel, W.
    Tammara, B.
    Udata, C.
    Comer, G.
    Gastonguay, M. R.
    Meng, X.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03): : 333 - 345
  • [28] What CATIE found: Results from the schizophrenia trial
    Swartz, Marvin S.
    Stroup, T. Scott
    McEvoy, Joseph P.
    Davis, Sonia M.
    Rosenheck, Robert A.
    Keefe, Richard S. E.
    Hsiao, John K.
    Lieberman, Jeffrey A.
    PSYCHIATRIC SERVICES, 2008, 59 (05) : 500 - 506
  • [29] Switching from olanzapine to ziprasidone: A twelve-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in patients with schizophrenia
    Si, T.
    Duan, Y. P.
    Su, Y.
    Dang, W.
    Deng, H.
    Tao, M.
    Liu, T.
    Chen, H.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 62 - 62
  • [30] Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia, or schizoaffectwe disorder
    Delbello, M
    Versavel, M
    Ice, K
    Miceli, J
    Kowatch, R
    Keller, D
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 80 - 81
12345